Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation

Cancer Immunology, Immunotherapy

Volumn 52, Issue 8, 2003, Pages 497-505

  Chakraborty, Nitya G ^a   Stevens, Robert L ^a   Mehrotra, Shikhar ^a   Laska, Elizabeth ^a   Taxel, Pamela ^a   Sporn, Jonathan R ^a   Schauer, Peter ^a   Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

CD8+ T cells; CTL activity; IFN ; PSA

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ARTICLE; CANCER PATIENT; CELL ASSAY; CELL CULTURE; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DONOR; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEASUREMENT; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DETERMINATION; STIMULATION; T LYMPHOCYTE; TECHNIQUE; TUMOR CELL; VOLUNTEER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0043160579     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0377-8     Document Type: Article

References (41)

1. Alexander RB, Brady F, Leffell MS, Tsai V, Celis E (1998) Specific T cell recognition of peptides derived from prostate specific antigen in patients with prostate cancer. Urology 51:150-157
2. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williums MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen specific T lymphocytes. Science 274:94-98
3. Anderson KS, Alexander J, Wei M, Cresswell P (1993) Intracellular transport of Class I MHC molecules in antigen processing mutant cell lines. J Immunol 151:3407-3411
4. Baecher-Allan C, Brown J, Freeman GJ, Halter DA (2001) CD4+ CD25+ Regulatory cells in human peripheral blood. J Immunol 167:1245-1253
5. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
6. Chakraborty A, Li L, Chakraborty NG, Mukheji B (2000) Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clin Immunol 94:88-98
7. Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells in vitro: Implications in designing tumor vaccines. J Immunol 162:5576-5583
8. Corman JM, Sercarz EF, Nanda NK (1998) Recognition of prostate specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 114:166-172
9. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen. J Natl Cancer Inst 89:293-300
10. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY (1998) Generation of human cytotoxic T lymphocyte lines directed against prostate specific antigens (PSA) employing a PSA oligoepitope peptide. J Immunol 161:3186-3194
11. Cox JH, Yewdell JW, Eisenlohr CL, Johnson PR, Bennink JR (1990) Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 247:715-718
12. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigenspecific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238
13. Guerder S, Carding SR, Flavell RA (1995) B7 Costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J Immunol 155:5167-5174
14. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J (2000) Human dendritic cells transfected with RNA encoding prostate specific antigen stimulate prostate specific CTL response in vitro. J Immunol 164:5508-5514
15. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Ming Chu T, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Can Res 43:1809-1818
16. Houghton A (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med. 180:1-4
17. Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of complementary DNA encoding prostate-specific membrane antigen. Cancer Res 33:227-230
18. Kappler JW, Roehm N, Marrack P (1987) T cell tolerance by clonal elimination in the thymus. Cell 49:273-280
19. Lee PP, Yee C, Savage PA, Davis MM (1999) Characterization of circulating T cells specific for tumor associated antigens in melanoma patients. Nature Med. 5:677-685
20. McNeel DG, Nguyen LD, Storrer BE, Vessella R, Lange PH, Disis ML (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urology 164:1825-1829
21. McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML.(2001) Naturally occurring prostate specific T cell responses of a Th 1 phenotype can be detected in patients with prostate cancer. Prostate 47:222-229
22. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed A, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961-1969
23. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A (1996) Phase I clinical trial: therapy for prostate cancer using autologous dendritic cell pulsed with HLA-0201-specific peptides from prostate specific membrane antigen. Prostate 29:371-380
24. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers MK, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boyton AL (1999) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39:54-59
25. Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch J (2000) Higher dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43:59-62
26. Pardoll DM (2000) Therapeutic vaccination for cancer. Clin Immunol 95:S44-S62
27. Perez-Diez A, Butterfield LH, Li L Chakraborty NG, Economou J, Mukherji B (1998) Generation of CD8+ and CD4+ T cell response to genetically engineered to express Mart-1/Melan A gene. Cancer Res 58:5305-5308
28. Ponniah S, Arah I, Alexander RB (2000) PSA is a candidate self antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 44:49-54
29. Nanda NK, Sercarz EE (1995) Induction of anti-self immunity to cure cancer Cell 82:13-17
30. Nijman HW, Houbiers JG, Vierboom MP, van der Brug SH, Drijfhout JW, D'amaro J, Kenemans P, Melief CJ, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215-1219
31. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramer reveals high numbers of antigen-experienced tumorspecific cytotoxic T lymphocytes. J Exp Med 188:1641-1650
32. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-178
33. Salgaller M (2000) Prostate cancer immunotherapy at the dawn of the new millennium. Expert Opin Investig Drugs 9:1217-1229
34. Salgaller ML, Tjoa BA, Lodge PA, Radge H, Kenny G, Boyton A, Murphy GP (1998) Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol 18:109-119
35. Sallustro F, Lannzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony stimulating factor plus Interleukin-4 and down regulated by tumor necrosis factor. J Exp Med 179:1109
36. Schmittel A, Keilholz U, Scheibenbogen C (1997) Evaluation of the interferon gamma Elispot assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 210:167-174
37. Schwartz RH, Mueler DL, Jenkins MK, Quill H (1989) T cell clonal anergy. Cold Spring Harbor Symp Quant Biol 56:605
38. Sercarz EE, Ixhmann PV, Ametani A et al (1993) Dominance and crypticity of T cell antigenic determinants. Ann Rev Immunol 11:729-766
39. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boyonton ML, Murphy GP (1999) GM-CSF as systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39:291-297
40. Terasawa H, Tsang K, Gulley J, Arlen P, Schlom J (2002) Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate specific antigen. Clin Can Res 8:41-53
41. Xue BH, Zhang Y, Sosman JA, Peace DJ (1997) Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 30:73-78